GSP Crop Science IPO Day 3: Check Latest GMP, Subscription Status & Key Highlights
The ?400 crore initial public offering (IPO) of GSP Crop Science will conclude today, 18 March 2026. Till the end of day 2, the IPO received a subscription of 0.98 times.?
GSP Crop Science IPO: Issue Details
- Issue Size: The GSP Crop Science IPO is a book-building issue of ?400 crore, consisting of a fresh issue of ?250 crore and an offer for sale (OFS) of ?160 crore.
- Price Band: The price band is set at ?304-?320 per share.
- Lot Size: 46 shares
- Minimum Investment: ?14,720 per lot for retail investors
- Book-running lead managers: Equirus Capital Private Limited and Motilal Oswal Investment Advisors Limited
- Registrar: MUFG Intime India Private Limited
- Listing: The shares are proposed to be listed on the NSE and the BSE on March 24, 2026.
GSP Crop Science? IPO Day 3: Subscription Details
[18-March-2026 11:06:00 hrs]
|
Investor Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
1.28 |
|
Non-Institutional Investors |
2.41 |
|
Retail Individual Investors (RIIs) |
0.24 |
|
Total |
1.00 |
Utilisation of IPO Proceeds
The net proceeds from the fresh issue will be used towards the following objectives:
- Repay/prepay outstanding borrowings
- General corporate purposes
Explore other Upcoming IPOs on BSE and NSE.
GSP Crop Science IPO GMP
According to media reports, the Grey Market Premium (GMP) of the GSP Crop Science IPO is reported at ?0 over the IPO price.?
GSP Crop Science? Business Overview?
GSP Crop Science is an agrochemical company with over four decades of industry experience in India. Their core operations revolve around the development, manufacturing, and commercialisation of crop protection products, including insecticides, herbicides, fungicides, and plant growth regulators. The company delivers effective solutions that help farmers enhance crop yield and improve agricultural productivity.
As of September 30, 2025, the company has secured 524 product registrations across formulations and technical portfolios, granted 102 patents to date, and has 108 additional patent applications under review.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.